Table 2

Summary of common recurrently amplified regionsa, b

Cytogenetic region
Mb start position (BAC)
Mb end position (BAC)
Size (Mb)
Genesc
No. cases

1p34
39.27 (RP11-528I12)
40.26 (RP11-747C18)
1.0
MACF1, PABPC4, TRIT1
3 (8%)
1q23
157.00 (RP11-735D24)
157.81 (RP11-812N5)
0.8
-
4 (11%)
2p25
9.42 (RP11-360P14)
10.34 (RP11-360P14)
0.9

3 (8%)
3p25
10.20 (RP13-635L13)
12.52 (RP11-738A2)
2.3
TATDN2, SEC13L1, VGLL4
3 (8%)
6p22
20.07 (RP11-345F7)
22.08 (RP11-630B10)
1.8

8 (21%)
8q22
101.23 (RP11-321E7)
102.99 (RP11-811I18)
1.8

5 (13%)
10q22
76.24 (RP11-368I19)
78.49 (RP11-272P2)
2.3
MYST4
3 (8%)
11q13
69.07 (CTD-2192B11)
70.20 (CTD-2011L13)
1.1
CCND1, ORAOV1, PPFIA1, CTTN
3 (8%)
16p13
10.59 (RP11-78D17)
12.84 (RP11-310B24)
2.3
NUBP1, DEXI, TXNDC11, ZC3H7A, RSL1D1, GSPT1
3 (8%)

aMapping data is based on the UCSC genome browser (May 2004 freeze), and listed regions represent core amplicons.

bOnly regions amplified in at least 3 cases are listed.

cGenes that showed top ranking expression levels when genomically amplified. More detailed data for the 6p22, 8q22, and for 2p25 is given in Additional file 3.

Heidenblad et al. BMC Medical Genomics 2008 1:3   doi:10.1186/1755-8794-1-3